What Is the Peptide Economy? Beyond the GLP-1 Boom

GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。